difenoxin/atropine (Rx)

Brand and Other Names:Motofen
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

difenoxin hcl/atropine

tablets: Schedule IV

  • 1 mg/0.025 mg
more...

Diarrhea

Initially 2 mg (2 tab) PO then 1 mg (1 tab) q3-4hr PRN loose stool; no more than 8 mg/day

Safety & efficacy not established

Diarrhea

Initially 2 mg (2 tab) PO then 1 mg (1 tab) q3-4hr PRN loose stool; no more than 8 mg/day

Next:

Interactions

Interaction Checker

and difenoxin/atropine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Nausea (6.7%)

            Somnolence (4%)

            Vomiting (3.3%)

            Xerostomia (3.3%)

            Headache (2.5%)

            Frequency Not Defined

            Dizziness

            Lightheadedness

            Abdominal discomfort

            Anticholinergic effects

            Previous
            Next:

            Warnings

            Contraindications

            <2 years old

            Hypersensitivity, infectious diarrhea, jaundice

            GI obstruction, hemorrhage, intestinal atony, myasthenia gravis, obstructive uropathy, reflux esophagitis, ulcerative colitis

            Cautions

            Closed-angle glaucoma, esophageal achalasia

            Hepatorenal disease, abnormal liver function

            Improvement of symptoms within 48 hr, if not, unlikely to be effective

            Do not exceed recommended dosage; reduce initial dosage for maintenance

            Pregnancy, breastfeeding

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: enters breast milk/not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Difenoxin: Acts on smooth muscle of intestinal tract, inhibiting GI motility & excessive GI propulsion

            Atropine: Subtherapeutic quantity of atropine is added to discourage deliberate overdose of diphenoxylate

            Pharmacokinetics

            Half-life elimination: 4.4 hr

            Onset: 45 min-1 hr

            Duration: 3-4 hr

            Peak Plasma Time: 40-60 min

            Excretion: Feces and urine as conjugates

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous